Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
To learn more about PWRM visit: http://www.Power3Medical.com
Maxwell Technologies Inc. (Nasdaq:MXWL)
MXWL reported that it has delivered BOOSTCAP ultracapacitor cells and multi-cell modules for more than 1,000 hybrid transit bus drive systems through the first three quarters of 2010, and sees continuing strong demand going forward.
MXWL develops, manufactures, and markets energy storage and power delivery products, and microelectronic products. MXWL markets and sells its products through direct and indirect sales organizations in North America, Europe, and Asia. MXWL was formerly known as Maxwell Laboratories, Inc. and changed its name to MXWL in 1996. MXWL was founded in 1965 and is headquartered in San Diego, California.
Maxygen, Inc. (Nasdaq:MAXY)
MAXY recently announced financial and business results for the quarter ended June 30, 2010.
MAXY, a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements. MAXY focuses on developing biocatalytic process technologies for pharmaceutical, energy, and industrial chemical applications. MAXY was founded in 1996 and is headquartered in Redwood City, California.
Mayflower Bancorp, Inc. (Nasdaq:MFLR)
MFLR recently reported net income of $336,000 or $0.16 per share for its first quarter ended July 31, 2010, a 45% improvement as compared to earnings of $232,000 or $0.11 per share for the same quarter last year. Diluted earnings per share for the quarter were $0.16 compared to $0.11 for the same quarter of last year.
MFLR operates as the bank holding company for Mayflower Co-operative Bank that provides various banking services to individuals and businesses primarily in southeastern Massachusetts. As of April 30, 2009, MFLR operated six full-service branch offices in Plymouth, Wareham, Rochester, Bridgewater, Lakeville, and West Wareham, Massachusetts. MFLR was founded in 1889 and is headquartered in Middleboro, Massachusetts.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).